Jian Kang Yuan Pharmaceutical Group's 2025 Independent Director Performance Report Released, Focusing on Finance and ESG Governance

Zhongfang Network data Healthyuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Healthyuan”) recently disclosed its 2025 annual report on the performance of independent directors. During the reporting period, independent director Ms. Peng Juan attended seven meetings of the board of directors and three general meetings of shareholders in total, and voted in favor of all proposals. As a member of the Audit Committee, the Remuneration and Appraisal Committee, and the Sustainable Development Committee of the board of directors, her key focus in fulfilling her duties included matters such as the quality of the company’s financial reporting, the development of the internal control system, related-party transactions, the remuneration of senior management, and equity incentives.

The report shows that in 2025, Healthyuan timely disclosed its regular reports and internal control evaluation reports. The independent directors considered the related financial information to be true and complete, and the internal control system to be sound and effective. For related-party transactions, proposals were considered including the ordinary related-party transactions between the company’s controlling subsidiary Jiaozuo Healthyuan and Jinguang Electric Power, providing a guarantee for loans to the latter, and the sale of assets. The independent director believed that the relevant decision-making procedures were legal and compliant, and no circumstances were found that would harm the interests of the company or its minority shareholders. In addition, during the reporting period, the company canceled some stock options due to failure to meet performance appraisal targets, and it extended the employee stock ownership plan and changed the management approach. The independent director believed that the related actions complied with the regulations.

In the report, independent director Ms. Peng Juan emphasized that, relying on her professional background in accounting and corporate governance, she continued to focus on the company’s sustainable development (ESG) strategy and actively participated in the work of relevant committees. She reviewed proposals such as the company’s sustainable development report and worked to help the company achieve high-quality, sustainable, and steady growth. The report also gave positive evaluations of the performance of other independent directors.

Overall, the independent directors believed that the company’s operations in 2025 were standardized. By actively participating in the work of the board of directors and its various special committees, they effectively fulfilled their supervisory responsibilities and played a positive role in safeguarding the legitimate rights and interests of the company and all shareholders.

A vast amount of information and precise interpretation—on the Sina Finance app